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The four myogenic basic helix-loop-helix proteins, MyoD, myogenin, Myf-5, and MRF4, can each activate skeletal muscle
differentiation when introduced into nonmuscle cells. During embryogenesis, each of these genes is expressed in a unique
but overlapping pattern in skeletal muscle precursors and their descendants. Gene knockout experiments have shown that
MyoD and Myf-5 play seemingly redundant roles in the generation of myoblasts. However, the role of either of these genes
during differentiation in vivo has not been determined. In contrast, a myogenin-null mutation blocks differentiation and
results in a dramatic decrease in muscle ®ber formation, yet the role of myogenin in the generation or maintenance of
myoblast populations is not known. Because myogenin possesses the same myogenic activity as MyoD and Myf-5 in vitro
and the expression patterns of these three genes overlap in vivo, we sought to determine if myogenin shares certain
functions with either MyoD or Myf-5 in vivo. We therefore generated mice with double homozygous null mutations in
the genes encoding MyoD and myogenin or Myf-5 and myogenin. These mice showed embryonic and perinatal phenotypes
characteristic of the combined defects observed in mice mutant for each gene alone. As shown by histological analysis
and expression of muscle-speci®c genes, the numbers of undifferentiated myoblasts and residual myo®bers were comparable
between myogenin-mutant homozygotes and the double-mutant homozygotes. Myoblasts isolated from neonates of the
combined mutant genotypes underwent myogenesis in tissue culture, indicating that no more than two of the four myogenic
factors are required to support muscle differentiation. These results demonstrate that the functions of myogenin do not
overlap with those of MyoD or Myf-5 and support the view that myogenin acts in a genetic pathway downstream of MyoD
and Myf-5. q 1995 Academic Press, Inc.
INTRODUCTION each exhibit distinct temporospatial expression patterns in
vivo, suggesting that they perform unique roles in the myo-
genic lineage. Myf-5, the ®rst member of the family to beThe discovery of the MyoD family of skeletal muscle-
expressed in the mouse, is initially detected in the derma-speci®c basic helix-loop-helix (bHLH) proteins, MyoD, my-
myotome at Embryonic Day 8 (E8) and continues thereafterogenin, Myf-5, and MRF4/Myf-6/herculin, has provided a
to be expressed in the dorsal regions of the differentiatinggenetic framework for understanding the mechanisms that
myotome (Ott et al., 1991; Smith et al., 1994). Myogenincontrol the formation of skeletal muscle during embryogen-
expression is observed throughout the myotome beginningesis (reviewed in Olson, 1990; Buckingham, 1992; Wein-
at E8.5 (Wright et al., 1989; Sassoon et al., 1989; Cheng ettraub, 1993; Rudnicki and Jaenisch, 1995). While these fac-
al., 1993; Yee and Rigby, 1993) and is followed by expressiontors share the ability to activate skeletal muscle differentia-
of MRF4 and MyoD at E9.5 and E10.5, respectively (Hinter-tion when expressed ectopically in nonmuscle cells, they
berger et al., 1991; Bober et al., 1991). In the limb buds,
Myf-5 expression is initiated at E10.5, followed by MyoD
and myogenin a half-day later.1 The ®rst two authors contributed equally to this work.
Gene knockout experiments have begun to reveal the2 To whom correspondence should be addressed. Fax: (713) 791-
9478. functions of the myogenic bHLH genes in the embryo. Mice
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lacking either Myf-5 or MyoD develop normal skeletal mus- the functions of these myogenic factors. These mice showed
phenotypes characteristic of the combined single gene mu-cle, whereas mice lacking both factors fail to form my-
oblasts (Rudnicki et al., 1992; Braun et al., 1992; Rudnicki tations, demonstrating that the functions of myogenin do
not overlap with those of either MyoD or Myf-5. Theseet al., 1993). These results indicate that MyoD and Myf-5
play overlapping roles in the genesis of myoblasts, although results argue against myogenin's involvement in parallel
myogenic pathways with other myogenic factors and sup-their conservation among the vertebrate classes strongly
suggests that both factors have unique functions as well. In port a model in which myogenin acts at a point in the
myogenic pathway downstream of Myf-5 and MyoD by reg-contrast to MyoD and Myf-5, in mice lacking myogenin,
myoblasts are correctly speci®ed and positioned, but there ulating target genes distinct from those of MyoD or Myf-5.
is a severe reduction in skeletal muscle ®bers (Hasty et al.,
1993; Nabeshima et al., 1993). Myogenin, therefore, appears
to be required for activation of the muscle differentiation MATERIALS AND METHODS
program. However, it is important to emphasize that these
results do not preclude a role for myogenin in the earlier Animal Crossing and Genotyping
phases of myogenesis. Indeed, transfection experiments
Mice heterozygous for the myogenin-null mutation (//have shown that myogenin can convert ®broblasts to my-
0) (Hasty et al., 1993) were crossed with mice homozygousoblasts and induce the expression of MyoD (Edmondson and
for the MyoD-null mutation (0/0) (Rudnicki et al., 1992)Olson, 1989; Wright et al., 1989).
or heterozygous for the Myf-5-null mutation (//0) (BraunFor reasons that are unclear, there are a small number of
et al., 1992). The resultant double heterozygous offspringdifferentiated muscle ®bers in myogenin-null mice which
were bred to produce double homozygous-null myogenin(0/do not represent a speci®c muscle ®ber type (Hasty et al.,
0)/MyoD(0/0) or myogenin(0/0)/Myf-5(0/0) mice. Mice1993; Venuti et al., 1995). Whether another myogenic bHLH
and embryos were genotyped by Southern blot analysis, us-factor substitutes for myogenin to support muscle-speci®c
ing genomic DNA isolated from tails, skin, and yolk sac.gene expression in these residual ®bers remains to be deter-
For the myogenin-null allele, genomic DNA was digestedmined.
with EcoRI and probed with a 32P-radiolabeled 900-bpThe muscle phenotype of myogenin-mutant mice repre-
EcoRI±SstI fragment of the myogenin cDNA. The probesents a state of arrested myoblast differentiation, implying
hybridizes with a 2.0-kb wild-type band and a 4.0-kb mutantthat other myogenic regulators are required for the initial
band. For the MyoD and Myf-5 mutations, Southern analy-commitment of precursor cells to the myogenic lineage. In
sis was performed as described by Rudnicki et al. (1992) anda genetic hierarchy, such factors could either work up-
Braun et al. (1992), respectively.stream of myogenin or their functions could overlap with
those of myogenin, which would suggest that they act in a
parallel myogenic pathway. In light of the fact that myo- Histology and Immunostaining
genin shows the same myogenic activity as MyoD and Myf-
5 in vitro and is expressed in a temporospatial pattern that Neonates and embryos were ®xed and embedded in paraf-
®n for immunocytochemistry and nucleic acid in situ hy-overlaps with those of MyoD and Myf-5 in vivo, it is reason-
able to expect that myogenin's functions might overlap at bridization (Lyons et al., 1990). Embryos were ®xed in 4%
paraformaldehyde in PBS for 48 hr at 47C. Neonates wereleast partially with those of MyoD or Myf-5 in vivo.
Because combinations of null mutations of different skinned prior to ®xing in 4% paraformaldehyde to improve
penetration and in®ltration of paraf®n.genes can uncover genetic functions that would otherwise
be masked when genes share overlapping functions, we Tissue sections were prepared for immunostaining by de-
paraf®nization and hydration as described by Venuti et al.combined the myogenin-null mutation with the MyoD- and
Myf-5-null mutations in order to determine whether myo- (1995). Initially, intrinsic peroxidase activity was quenched
by incubation in 3.0% H2O2 in methanol for 30 min fol-genin might play a role in early steps in the myogenic path-
way. In principle, at least three potential outcomes might lowed by blocking nonspeci®c antigenic sites by incubation
in 2% BSA/2% horse serum/PBS. The primary and second-be envisioned by these combined mutations. (1) There could
be an absence or a reduction of myoblasts with either of ary antibody incubations were performed for 1 hr each and
excess antibody was removed with three successive 10-minthe combined mutations, which would suggest that myo-
genin has a role in the generation of myoblasts that overlaps washes in PBS. The monoclonal anti-skeletal MHC embry-
onic fast isoform (Sigma) was diluted 1:400 in blockingwith the role of either MyoD or Myf-5. (2) The combined
mutations might reveal unanticipated functions of the buffer and the polyclonal anti-desmin antibody (Sigma) was
diluted 1:100 in blocking buffer. Biotinylated secondary an-genes by resulting in a phenotype different from either mu-
tation alone or from the MyoD/Myf-5 double mutation. (3) tibodies speci®c to mouse and rabbit IgG (Zymed) were di-
luted 1:400. Subsequently, tissue sections were incubatedThe phenotype of the double mutations could represent the
combined phenotypes of the single mutations, indicating with avidin-conjugated HRP at a dilution of 1:200 in PBS
for 10 min. Excess HRP was removed with three washesthat myogenin's functions do not overlap with those of
MyoD or Myf-5. Our results support the latter model for with PBS and the antigen±antibody complex was visualized
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using 3,3 *-diaminobenzidine (Sigma). The sections were TGGCTCC-3* and 5*-TGCTGGAGGCTGAGGCATCC-
3 *, with a 453-bp PCR product; muscle creatine kinase (Hol-counterstained with hematoxylin and mounted with Per-
mount. lenberg et al., 1993) 5*-CAATAAGCTTCGCGATAA-
GGAG-3* (nt -189 to -210 and 5*-GATGGGATCAAACAG-Analysis of MRF4 expression was performed on 10-mm
transverse sections of neonate hindlimbs. Neonatal tissue GTCCTTG-3* (nt -348 to -327), with a 160-bp PCR product.
To control for equal amounts of input, template primerswas frozen and cryosectioned as described by Smith et al.
(1994). Prior to immunostaining, sections were hydrated in speci®c to the ribosomal protein L7 (Hollenberg et al.,
1993), 5*-GGAGCTCATCTATGAGAAGGC-3* (nt -231PBS and ®xed in 3.7% paraformaldehyde for 5 min followed
by 0.1% Triton X-100 for 5 min. All other steps were similar to -251) and 5*-AAGACGAAGGAGCTGCAGAAC-3* (nt -
432 to -412), with a 202-bp PCR product, were used.to those performed for immunostaining of paraf®n-embed-
ded tissue except that the antigen±antibody complex was
In Situ Hybridizationvisualized using AEC (Zymed). The monoclonal anti-MRF
antibody (kindly provided by S. Konieczny) was diluted In situ hybridization using a muscle-speci®c marker was
1:500 in blocking buffer. performed as described in Lyons et al. (1990). The embry-
onic fast isoform of skeletal myosin heavy chain (MHCemb)
riboprobe was described in Lyons et al. (1990). TransverseRNA Isolation and Reverse Transcription/PCR
sections 7 mm thick through approximately the same ana-
Total cellular RNA was isolated from limb muscle dis- tomical level were examined for E13.5 wild-type and mu-
sected from newborn mice. RNA was isolated from muscle tant embryos.
tissue extracted by homogenizing in TRIzol (Gibco BRL) for
Primary Myoblast Cultures2 min in 30-sec intervals. Phase separation was performed
by the addition of chloroform and centrifugation at 12,000g Primary myoblast cultures were established from wild-
for 15 min at 47C. The aqueous phase was precipitated with type and mutant neonates as described by Freshney (1987).
0.5 ml of isopropanol. The RNA was pelleted at 12,000g for Muscle tissue dissected from all four limbs was dissociated
10 min at 47C, washed with 75% ethanol, and resuspended by ®ne mincing with microdissecting scissors followed by
in DEPC-treated water. treatment with collagenase (100 units/ml; Gibco) for 60 min
Total cellular RNA was reverse-transcribed to synthesize at 377C. The enzymatic digestion was stopped by the addi-
single-stranded cDNA. The RNA was heated to 657C for 5 tion of Dulbecco's modi®ed Eagle's medium (DMEM) con-
min and then placed on ice for 5 min. Reverse transcription taining 15% fetal bovine serum (FBS). Contaminating ®-
was performed on 1 mg of RNA in 50 mM Tris±HCl (pH broblasts were selectively removed by preplating the cell
8.3), 75 mM KCl, 3 mM MgCl2, 3.3 mM DTT, 0.5 mM of suspension for 1 hr at 377C, 7% CO2. The myoblasts were
each dNTP (Pharmacia); 200 ng of random hexamer primer plated on 10-cm2 dishes coated with 0.1% gelatin and grown
(Boehringer-Mannheim Biochem.); RNase inhibitor; and in 15% FBS in DMEM supplemented with 5 nM bFGF. Cells
200 U of Mo-MuLV reverse transcriptase (Gibco BRL) at were fed the following day and every third day thereafter.
427C for 1 hr. To induce differentiation, the growth medium was changed
PCR ampli®cation was typically performed using the fol- to 2% horse serum (HS) in DMEM.
lowing conditions. Two microliters of single-stranded MHC was detected in primary myoblast cultures by indi-
cDNA from a 30-ml reverse transcription reaction was am- rect immuno¯uorescence. Cells were washed with PBS and
pli®ed in 50 mM KCl, 10 mM Tris±HCl, 1.5 mM MgCl2, then ®xed with 100% ethanol for 7 min at 0207C. After
0.01% gelatin, 0.2 mM of each dNTP, 100 ng of each gene- rapid washing in PBS, the cells were incubated in blocking
speci®c primer, 2.5 U Taq polymerase (Boehringer-Mann- buffer (2% BSA/2% HS/PBS) for 30 min at room tempera-
heim Biochem.) and 0.1 liter [a-32P]dCTP (3000 Ci/mmoles) ture. MHCemb (fast isoform) monoclonal antibody (Sigma)
(NEN). A typical temperature cycle was 957C for 5 min for was added to the cells in blocking buffer at a dilution of
one cycle followed by 957C for 1 min, 627C for 30 sec, and 1:400. The cells were then washed with 0.1% NP-40/PBS,
727 for 30 sec for 23 cycles. The PCR products were run out followed by incubation with a biotinylated goat anti-mouse
on a 6% acrylamide gel followed by analysis on a phos- antibody (Sigma). Unbound antibody was removed with
phorimager. The intensity of each band was quanti®ed and 0.1% NP-40/PBS and the cells were treated with an avidin±
corrected according to internal controls. The PCR reactions FITC conjugate (Sigma). Excess conjugate was removed and
were in the linear range with respect to input RNA. MHC-expressing cells were visualized with a ¯uorescence
Primers for detecting muscle-speci®c transcripts and microscope.
sizes of PCR products were: MyoD (Hollenberg et al., 1993)
5*-AGGACACGACTGCTTTCTTC-3* (nt -23 to -4) and 5*- RESULTS
GCACCGCAGTAGAGAAGTGT-3* (nt -367 to -348), with
Characterization of Myogenin/MyoD- anda 390-bp PCR product; Myf-5 (Hannon et al., 1992) 5*-TGT-
Myogenin/Myf-5-Null MiceATCCCCTCACCAGAGGAT-3* and 5*-GGCTGTAAT-
AGTTCTCCACCTGTT-3*, with a 379-bp PCR product; To generate mice with homozygous null mutations in
genes for both myogenin and MyoD, MyoD(0/0) mice wereMRF4 (Hannon et al., 1992) 5*-GAGAGGAACACGTTC-
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TABLE 1
Genotypes from Myogenin(//0)/MyoD(//0) Intercrosses
Genotype 1 2 3 4 5a 6a 7a 8 9
Myogenin /// /// //0 //0 0/0 0/0 0/0 //0 ///
MyoD /// //0 /// //0 /// //0 0/0 0/0 0/0
Predicted % 6.25 12.5 12.5 25.0 6.25 12.5 6.25 12.5 6.25
Observed % (No.) 6.4(2) 12.8(4) 9.3(3) 25.0(8) 6.4(2) 9.3(3) 6.4(2) 9.3(3) 9.3(3)
Note. Myogenin(//0)/MyoD(//0) mice were intercrossed. The nine expected genotypes are shown with their predicted and observed
frequencies expressed as percentage of total offspring. The numbers in parenthesis indicate the actual number of offspring obtained with
that genotype.
a Lethality of the genotype at birth.
crossed with myogenin(//0) mice and offspring with the To determine the consequences of the combined null mu-
tations on muscle formation, we analyzed histological sec-genotype myogenin(//0)/MyoD(//0) were then inter-
crossed. Myogenin(0/0)/Myf-5(0/0) mice were generated tions of muscle from the tongue, dorsal body wall, and hind
limb of wild-type and mutant neonates. As reported pre-by mating myogenin(//0) mice with Myf-5(//0) mice fol-
lowed by intercrossing of offspring heterozygous for both viously (Hasty et al., 1993; Nabeshima et al., 1993), the
presumptive muscle-forming regions of myogenin(0/0)myogenin and Myf-5. Mice arising from the above crosses
were genotyped at birth or after weaning. Nine potential mice are populated primarily by unfused myoblasts and con-
tain only occasional multinucleated muscle ®bers (Figs. 1B,genotypes are expected among the offspring of the two dou-
ble heterozygote intercrosses, with the double homozygous 1F, and 1J), as can be clearly seen when these mice are
compared to their wild-type littermates (Figs. 1A, 1E, andnull genotypes being observed with a frequency of 6.25%.
The genotypes that were observed were in close agreement 1I). The extent of residual myo®bers in the myogenin-mu-
tant neonates varied somewhat when different litters werewith the predicted genotypes, indicating that the combined
mutations did not lead to embryonic death (Tables 1 compared, but we always observed a severe reduction of
myo®bers in a background of mononucleate myoblasts. Ne-and 2).
At the time of birth, offspring of all genotypes were alive. onates bearing the combined double null mutations for ei-
ther myogenin/Myf-5 (Figs. 1C, 1G, and 1K) or myogenin/However, mice homozygous for the myogenin- or Myf-5-
null alleles died within the ®rst few minutes after birth. MyoD (Figs. 1D, 1H, and 1L) showed a muscle phenotype
indistinguishable from that of myogenin(0/0) mice. ThePerinatal death of myogenin- and Myf-5-null mice is due to
the absence of functional skeletal muscle and ribs, respec- extent of differentiated myo®bers seen in either of the dou-
ble mutants varied, but the variation was the same as thattively (Hasty et al., 1993; Braun et al., 1992). Myf-5(//0)/
MyoD(0/0) mice were previously shown to be nonviable, seen with the myogenin(0/0) animals.
To speci®cally detect differentiated muscle cells, we im-suggesting that in the absence of MyoD, two Myf-5 alleles
are required for survival (Rudnicki et al., 1993). In contrast, munostained sections of muscle from neonatal mice of the
three genotypes for MHC (Fig. 2). Sagittal sections of tonguewe found that offspring of the genotype myogenin(//0)/
MyoD(0/0) were fully viable, suggesting that myogenin- or axial muscle from wild-type mice showed MHC-positive
staining in densely packed, well-organized myo®bers (Figs.dependent aspects of muscle development are insensitive
to the level of MyoD. 2A and 2B), while myogenin(0/0) mice had fewer positive
TABLE 2
Genotypes from Myogenin(//0)/Myf-5(//0) Intercrosses
Genotype 1 2 3 4 5a 6a 7a 8a 9a
Myogenin /// /// //0 //0 0/0 0/0 0/0 //0 ///
Myf-5 /// //0 /// //0 /// //0 0/0 0/0 0/0
Predicted % 6.25 12.5 12.5 25.0 6.25 12.5 6.25 12.5 6.25
Observed % (No.) 6.3(7) 9.9(11) 15.3(17) 27.9(31) 7.2(8) 9.9(11) 5.4(6) 11.7(13) 6.3(7)
Note. Myogenin(//0)/Myf-5(//0) mice were intercrossed. The nine expected genotypes are shown with their predicted and observed
frequencies expressed as percentage of total offspring. The numbers in parenthesis indicate the actual number of offspring obtained with
that genotype.
a Lethality of the genotype at birth.
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cells and these were highly disorganized (Figs. 2C and 2D). lower level in myogenin(0/0) mutants than in wild-type
controls, indicating delayed differentiation as observed pre-Compared to the myogenin(0/0) mice, similar numbers of
differentiated cells were observed in tongue and axial mus- viously (Fig. 4; Venuti et al., 1995). Expression was not fur-
ther reduced in the myogenin(0/0)/Myf-5(0/0) mutant.cles from either myogenin(0/0)/MyoD(0/0) mice (Figs. 2E
and 2F) or myogenin(0/0)/Myf-5(0/0) mice (Figs. 2G and Similarly, no notable difference was observed in the level of
MHC transcripts between myogenin(0/0) and myogenin(0/2H). Because the absence of Myf-5 or MyoD did not enhance
the severity of the myogenin-mutant phenotype, these re- 0)/MyoD(0/0) embryos (data not shown). These results are
consistent with nonoverlapping functions of myogeninsults argue that the functions of myogenin are distinct from
those of either Myf-5 or MyoD. The presence of residual with either MyoD or Myf-5 in the temporal pattern of differ-
entiation. This observation was con®rmed by immuno-differentiated muscle ®bers in mice with the combined null
mutations also demonstrates that neither MyoD or Myf-5 staining the presumptive muscle regions of the limbs of
E13.5 embryos with anti-MHC and anti-desmin antibodiesalone is required for the differentiation of these cells in the
absence of myogenin. (data not shown). A decrease in the level of MHC expression
was observed in the myogenin-null embryos compared toThe predominant phenotype of the double mutants was
the absence of differentiated muscle cells. To determine if that in the wild-type embryos. MHC expression in the myo-
genin-null embryos was comparable to that in the doublethe MHC-negative population of cells in the presumptive
muscle-forming regions of the double mutants were my- mutants. In contrast, all cells in the muscle of the wild-
type, myogenin(0/0), myogenin(0/0)/MyoD(0/0), and myo-oblasts, we immunostained adjacent sections of neonatal
mice with an antibody against desmin, which is expressed genin(0/0)/Myf-5(0/0) embryos stained for desmin (data
not shown).in undifferentiated myoblasts as well as differentiated myo-
®bers. In muscle of the myogenin(0/0) mice, anti-desmin
antibody positively stained both myo®bers and adjacent Expression of Muscle-Speci®c Genes in Myogenin/mononucleated cells. This could best be seen in the tongue,
MyoD- and Myogenin/Myf-5-Null Micewhere at high magni®cation (Fig. 3A), greater than 50%
of the mononucleated cells were desmin-positive. Similar To determine whether the double null mutations affected
expression of the remaining two myogenic bHLH genes, welevels of desmin-positive mononucleated cells were also ob-
served in the myogenin(0/0)/MyoD(0/0) (Fig. 3B), and myo- measured their expression in muscle from neonates by RT±
PCR. As reported previously, Myf-5 transcripts were ex-genin(0/0)/myf5(0/0) (Fig. 3C) neonate mice. These results
demonstrate that commitment of cells to the myogenic lin- pressed at about a twofold higher level in MyoD(0/0) mice
compared to wild type (Fig. 5A, lanes 3 and 4). When theeage occurs similarly in the double mutants, arguing against
an overlap in function between myogenin and either MyoD myogenin(0/0) and MyoD(0/0) mutations were combined,
we observed approximately the same level of Myf-5 expres-or myf5 for the speci®cation of cells to the muscle lineage.
The identity of the desmin-negative cells remains to be sion as with the MyoD(0/0) mutation alone (Fig. 5A, lanes
2 and 3). The upregulation of Myf-5 expression appears todetermined. It is likely that these cells are not in the myo-
genic lineage, since immunostaining with a MyoD-speci®c be a speci®c response to the MyoD-null mutation because
the level of Myf-5 expression was not affected by the myo-antibody (Hasty et al., 1993) revealed a similar percentage
of negative mononucleated cells. genin-null mutation alone (Fig. 5A, lane 1). MRF4 was ex-
pressed at dramatically reduced levels in myogenin(0/0)We have shown earlier that myogenin's absence affects
myogenesis at late stages of embryo development (E14.5 to mice (Fig. 5A, lane 1), while it was expressed at wild-type
levels in MyoD(0/0) mice (Fig. 5A, lanes 3 and 4). Therebirth) more severely than at early stages (E8.5 to E14.5)
(Venuti et al., 1995). Thus, in myogenin mutants, muscle was an insigni®cant diminution in MCK mRNA expression
in MyoD(0/0) mice (Fig. 5A, lanes 3 and 4) and virtualmasses form during early stages and muscle-speci®c mark-
ers are expressed. However, even at early stages, muscle absence of the transcript in mice lacking myogenin (Fig.
5A, lanes 1 and 2).differentiation is delayed and muscle markers are not ex-
pressed at normal levels. It was possible that either or both As reported previously (Hasty et al., 1993) and shown in
Fig. 5B (lanes 1 and 4), MyoD expression was not signi®-of the double homozygous mutants would exhibit a more
severe phenotype than the myogenin(0/0) mutant during cantly altered in myogenin(0/0) mice compared to that in
the wild-type controls. MyoD expression was reduced byembryogenesis. To examine this possibility, we monitored
the extent of muscle differentiation in E13.5 embryos by 1.5-fold in Myf5(0/0) mice (Fig. 5B, lane 3). A similar de-
crease was also observed in the myogenin(0/0)/Myf5(0/0)detection of MHC transcripts. In situ hybridization of trans-
verse sections showed that MHC was expressed at a slightly mice (Fig. 5B, lane 2). MRF4 RNA levels were reduced to
FIG. 1. Histology of muscles in wild-type and mutant neonates. Parasagittal thin sections of muscles from neonatal mice of the indicated
genotypes were stained with hematoxylin and eosin. (A±D) Tongue. (E±H) Axial muscle of dorsal body wall. (I ±L) Forelimb muscle. The
genotypes are indicated above each set of panels. Magni®cation 2001.
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FIG. 4. Detection of MHC transcripts by in situ hybridization of E13.5 embryos. Transcripts for the embryonic fast isoform of skeletal
MHC were detected by in situ hybridization to transverse sections from E13.5 embryos at the level of the forelimb. MHC expression was
reduced to a comparable level in myogenin(0/0) and myogenin(0/0)/Myf-5(0/0) embryos. n, neural tube; ¯, forelimb.
FIG. 2. Expression of MHC in tongue and axial muscles of wild-type and mutant neonates. Paraf®n-embedded parasagittal thin sections
of muscle from the neonatal mice of the indicated genotypes were stained with antibodies speci®c to the fast isoform of skeletal MHC.
(A±D) Tongue, (E±H) axial muscle of the dorsal body wall. The antibody was visualized through HRP enzymatic reaction using DAB as
the chromogen. The genotypes are indicated above each set of panels. Magni®cation 4001.
FIG. 3. Expression of desmin in tongue muscle of mutant neonates. Paraf®n-embedded parasagittal thin sections of muscle from neonatal
mice of the indicated genotypes were stained with antibodies speci®c to desmin. The antibody was visualized through HRP enzymatic
reaction using DAB as the chromogen. Magni®cation 6001.
Copyright q 1995 by Academic Press, Inc. All rights of reproduction in any form reserved.
/ m4070$8019 10-06-95 17:16:37 dba Dev Bio
45Unique Functions of Myogenin
considered the possibility that MRF4 might be expressed in
the residual muscle ®bers in these mutant mice. We there-
fore examined the expression of MRF4 protein in sections
of the limbs of wild-type and myogenin-null mice. As
shown in Fig. 6, MRF4 protein was detected speci®cally
in the differentiated muscle ®bers of myogenin-null mice,
although for reasons that are not clear the staining was not
restricted to nuclei. The expression of MRF4 in these ®bers
correlated with the expression of MHC. These results sug-
gest that MRF4 may support the differentiation of these
residual ®bers in the myogenin-mutant mice and by extrap-
olation in both of the double mutants.
Potential of Mutant Myoblasts to Form Myotubes
in Vitro
Although myogenin's absence prevents myoblasts from
differentiating in vivo, this is not the case in vitro (Nabes-
hima et al., 1993). Myoblasts from myogenin-mutant limbs,
when cultured in vitro, readily fuse and form multinucle-
ated myotubes. We asked if the myogenin/MyoD and myo-
genin/Myf-5 double-mutant myoblasts had the same poten-
tial. Cells obtained from the hind limbs of neonates were
cultured under conditions of low serum to promote my-
oblast differentiation. Cultures from limbs of all single and
double mutant genotypes showed extensive myotube differ-
entiation, comparable in their rate of formation and number
of myotubes to wild-type controls, as assessed by phase-
FIG. 5. Detection of muscle-speci®c mRNAs by RT±PCR in mus- contrast microscopy and immunostaining with MHC anti-
cle from wild-type and mutant neonates. Transcripts for MCK, bodies (Fig. 7). These results show that myogenesis can oc-
Myf-5, MRF4, MyoD, and L7 were measured by quantitative RT± cur in vitro in the absence of myogenin and either MyoD
PCR using total cellular RNA from carcasses of neonatal lit-
or Myf-5.termates arising from a myogenin(//0)/MyoD(//0) (A) and a
myogenin(//0)/Myf-5(//0) (B) intercross. Genotypes are indicated
above each lane. To control for equal input of total RNA, the level
DISCUSSIONof RNA for the constitutively expressed ribosomal protein L7 was
determined. PCR reactions were performed under conditions of
linearity with respect to input RNA. PCR ampli®cation was per- Based on the absence of myoblasts in MyoD/Myf-5-null
formed in duplicate. A representative experiment is shown. mice and the block to myoblast differentiation in myo-
genin-null mice, it has been proposed that MyoD and Myf-
5 play apparent overlapping roles in the formation of my-
oblasts, whereas myogenin acts later in the muscle differen-
near background levels in the myogenin mutant and myo- tiation pathway (Weintraub, 1993; Olson and Klein, 1994;
genin/Myf5 double-mutant mice, while they were normal Rudnicki and Jaenisch, 1995). The failure of the Myf-5- or
in the Myf5 mutant (Fig. 5B, lane 3) as previously shown MyoD-null mutations alone to affect muscle development
by Braun et al. (1992). MCK expression was normal in Myf5- could be explained if both factors were expressed in the
null mice, but was dramatically reduced in myogenin mu- same cells or if they were expressed in separate populations
tants or myogenin/Myf5 mutants. These results show that of myoblasts, such that elimination of one population by
the expression of MRF4 in the double-mutant neonates is removing either Myf-5 or MyoD would be compensated for
identical to what is observed in the myogenin-null mice by expansion of the other population. Recent studies sug-
while the expression of MyoD is similar to that in the Myf5 gest the existence of separate Myf-5- and MyoD-dependent
null. myogenic lineages. In Myf-5-null embryos, there is a 2-day
delay in formation of the myotome and in expression of
myogenin, until MyoD expression is initiated (Braun et al.,MRF4 Is Expressed in the Residual Muscle Fibers
1994). These results demonstrate that MyoD expression isin Myogenin-Null Mice
independent of Myf-5 and probably de®nes a separate myo-
genic lineage, although other explanations are also possible.Although MRF4 transcripts were not detectable in total
RNA from the carcasses of neonates lacking myogenin, we In this regard, immunohistochemical detection of the four
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FIG. 7. In vitro differentiation of myoblasts from wild-type and mutant mice. Limb muscle from neonates of the indicated genotypes
was dissociated and myoblasts were cultured in vitro as described under Materials and Methods. Following exposure to differentiation
medium for 4 days, cells were stained for MHC expression using anti-MHC antibody.
myogenic bHLH proteins in the developing somites sug- newly compartmentalized somites, myogenin is the only
myogenic bHLH protein detected in the ventral myotomegests that the dermamyotome is comprised of at least two
subdomains that express different combinations of the myo- (Smith et al., 1994). This early expression of myogenin,
combined with the ability of myogenin to induce MyoDgenic factors (Smith et al., 1994). Myf-5 is expressed in the
dorsal dermamyotome, beginning at E8.0. In contrast, at the expression in transfected cells (Thayer et al., 1989; Brennan
et al., 1990), raises the possibility that it might also controllevel of the forelimb bud, MyoD is ®rst expressed in the
ventral myotome on E9.5. At these early stages of myogen- events in the myogenic pathway prior to differentiation. If
so, then combining the myogenin null mutation with nullesis in the somites, the expression domains of Myf-5 and
MyoD appear to be mutually exclusive, whereas at later mutations of MyoD or Myf-5 would be expected to uncover
a novel phenotype, not revealed by the individual gene mu-stages they are overlapping.
Myogenin transcripts are expressed throughout the myo- tations.
When the myogenin-null mutation was combined withtome beginning at E8.5 (Wright et al., 1989; Sassoon et al.,
1989; Cheng et al., 1993; Yee and Rigby, 1993). Some inves- the Myf-5- or MyoD-null mutations, no additional muscle
defects were observed. These results suggest that myogen-tigators have reported that myogenin protein does not ap-
pear in the somites until E10.5 (Cussella-DeAngellis et al., in's functions are restricted to the control of myoblast dif-
ferentiation and do not overlap with the early functions of1992), while others have found expression of the protein to
be coordinated with the mRNA (Smith et al., 1994). In either Myf-5 or MyoD. We also observed no dosage effects of
Copyright q 1995 by Academic Press, Inc. All rights of reproduction in any form reserved.
/ m4070$8019 10-06-95 17:16:37 dba Dev Bio
48 Rawls et al.
Myf-5 or MyoD on the myogenin phenotype; one functional differentiate in vitro and have observed that they form myo-
myogenin gene was suf®cient to support muscle develop- tubes and express muscle differentiation markers to an ex-
ment in mice homozygous for the mutant Myf-5 or MyoD tent similar to normal myoblasts. This provides further evi-
genes. This is in contrast to the effects of Myf-5 on MyoD; dence for the conclusion that the complete muscle differen-
in a MyoD-null background, a single Myf-5 gene is insuf®- tiation program can be initiated in the absence of two of
cient to support normal muscle development (Rudnicki et the four myogenic factors. Notably, MRF4 is expressed in
al., 1993). wild-type and myogenin-mutant myoblasts in vitro, making
Despite the severe de®ciency of skeletal muscle that re- it a likely candidate to be supporting differentiation of these
sults from the myogenin-null mutation, a few muscle ®bers cells.
are able to form and differentiate in myogenin-mutant mice. If all of the myogenic factors can activate myogenesis in
The activation of muscle gene expression in these residual transfection assays, why do they apparently perform differ-
muscle ®bers could conceivably be dependent on MyoD or ent functions in vivo? The simplest explanation is that the
Myf-5. However, our results demonstrate that there are a speci®cities of the factors are lost in transfection assays in
comparable number of differentiated ®bers in mice harbor- which the factors are overexpressed. In vivo, the distinct
ing the combined myogenin/MyoD or myogenin/Myf-5 mu- functions of the different factors could result from their
tations to that in the myogenin-null mutation alone. Thus, unique expression patterns. If, for example, it is the pres-
neither MyoD nor Myf-5 alone is necessary to support myo- ence of a myogenic bHLH protein at a speci®c point in
genesis in these muscle ®bers. the myogenic lineage that is important, then the different
The formation of residual differentiated muscle ®bers in phenotypes that arise from the different mutations may
myogenin/MyoD- and myogenin/Myf-5-mutant mice dem- simply reveal the consequences of removing a bHLH protein
onstrates that muscle differentiation can occur in a subset at that point in the myogenic pathway. Alternatively, each
of cells in vivo with only two of the four myogenic factors. bHLH factor may possess intrinsic activities that distin-
Based on their sequence relatedness (Atchley et al., 1994), guish them from the others. By swapping the control regions
their expression patterns, and the consequences of muta- of the different myogenic bHLH genes, it should be possible
tions in vivo, it appears that the myogenic bHLH factors to distinguish between these possibilities.
can be grouped into two different classes, with MyoD and The four myogenic bHLH factors dimerize comparably
Myf-5 acting in myoblasts and myogenin controlling later with E-proteins and bind the same DNA sequence. This
events of differentiation. MRF4 is expressed late in the mus- raises the intriguing question as to how they are able to
cle differentiation program, suggesting that its functions regulate different sets of target genes within the myogenic
might overlap with those of myogenin. In this regard, we
lineage. Presumably, MyoD and Myf-5 control the expres-
have recently generated MRF4-null mice and have found
sion of genes that establish myoblast identity, whereas my-
that they are viable with virtually normal skeletal muscle
ogenin controls differentiation-speci®c genes. In that myo-(Zhang et al., 1995). However, myogenin expression is ele-
genin is expressed with MyoD and Myf-5 in overlappingvated in muscle from MRF4-null mice, consistent with the
sets of cells in the myotome (Smith et al., 1994), it is re-possibility that it can compensate for MRF4. Braun and
markable that the functions of these factors are so different.Arnold (1995) have produced mice lacking Myf-5 and MRF4.
Previous studies have suggested that the nonconservedThese mice also have normal skeletal muscle, although
amino and carboxyl termini of the factors may allow themthey die due to the absence of ribs, which results from the
to cooperate with different combinations of transcriptionlack of Myf-5 expression. The phenotype of their mice also
factors that bind sites surrounding the E-boxes in muscledemonstrates that myogenin and MyoD are suf®cient to
gene control regions (Chakraborty and Olson, 1991; Mak etsupport normal muscle development in vivo.
al., 1992).MRF4 fails to be expressed in undifferentiated myoblasts
Genetic pathways in which related bHLH proteins act atin myogenin-null mice. However, in the residual muscle
different steps in a cell lineage to control the formation of®bers that form in the mutant, MRF4 is expressed at high
precursor cells and their subsequent differentiation appearlevels. While we favor the possibility that MRF4 supports
to be a common means of specifying cell fates in a varietydifferentiation of these ®bers, we cannot rule out the possi-
of lineages. The genetic pathway that controls the forma-bility that MRF4 is upregulated in these ®bers as a conse-
tion of neurosensory cells in Drosophila is particularly simi-quence of their differentiation. Combining the myogenin-
lar to the myogenic pathway in vertebrates (Jan and Jan,and MRF4-null mutations will eventually distinguish be-
1993). The genes achaete, scute, and asense, which are con-tween these possibilities.
tained in the achaete±scute complex, share extensive ho-When myogenin-null myoblasts that cannot differentiate
mology within their bHLH regions and can each inducein vivo are placed in tissue culture, they form myotubes as
neurogenesis when expressed ectopically in Drosophila.ef®ciently as wild-type myoblasts. This raises the possibil-
During embryogenesis, these genes show distinct but over-ity that other myogenic bHLH factors are able to initiate the
lapping expression patterns in the neurogenic lineage. Mu-myogenic program in vitro, but are prevented from doing so
tations of these genes have revealed that achaete and scutein vivo. We have examined the ability of myogenin(0/0)/
MyoD(0/0) and myogenin(0/0)/Myf-5(0/0) myoblasts to play similar roles in the generation of neuroblasts, while
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Edmondson, D. G., and Olson, E. N. (1989). A gene with homologyasense and another bHLH gene deadpan regulate neuroblast
to the myc similarity region of MyoD1 is expressed during myo-differentiation.
genesis and is suf®cient to activate the muscle differentiationThe myogenic bHLH factors are highly conserved across
program. Genes Dev. 3, 628 ±640.vast phylogenetic distances, which suggests that their func-
Freshney, R. I. (1987). ``Culture of Animal Cells. A Manual of Basictions and target genes are also conserved. However, inverte-
Technique,'' 2nd ed. Wiley-Liss, New York.
brate species that have been investigated contain only a Hannon, K., Smith, C. K., Bales, K. R., and Santerre, R. F. (1992).
single myogenic bHLH gene, whereas vertebrates contain Temporal and quantitative analysis of myogenic regulatory and
four (Olson and Klein, 1994). The distinct genetic functions growth factor gene expression in the developing mouse embryo.
of MyoD and Myf-5 in muscle cell determination and of Dev. Biol. 151, 137±144.
myogenin in muscle cell differentiation may have evolved Hasty, P., Bradley, A., Morris, J. H., Venuti, J. M., Olson, E. N., and
Klein, W. H. (1993). Muscle de®ciency and neonatal death into expand the mechanisms whereby muscle development
mice with a targeted mutation in the myogenin gene. Naturecan be regulated.
364, 501±506.
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